TheraRadar

Pharma Intelligence, Simplified

Landscape → Metabolic

NASH/NAFLD

487 clinical trials

113 active
/
487 total (since 2015)
20
Phase 1 Active
152 total
59
Phase 2 Active
262 total
21
Phase 3 Active
55 total
19
Phase 4 Active
54 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
GSK 5 1 0
Akero Therapeutics, Inc 4 2 0
Madrigal Pharmaceuticals, Inc. 3 3 0
Novo Nordisk 2 9 0
Corcept Therapeutics 2 3 1
89bio, Inc. 2 3 0
Merck 1 4 1
Gannex Pharma Co., Ltd. 1 3 1
Rivus Pharmaceuticals, Inc. 1 3 0
Guangdong Raynovent Biotech Co., Ltd 1 2 0
Inventiva Pharma 1 2 0
Hepion Pharmaceuticals, Inc. 1 2 0
MediciNova 1 1 0
Hanmi Pharmaceutical Company Limited 1 1 0
Neuraly, Inc. 1 1 0
NCT06419374 RECRUITING
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
89bio, Inc. n=762
NCT06528314 RECRUITING
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc n=1,150
NCT04822181 ACTIVE NOT RECRUITING
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Novo Nordisk A/S n=1,205
NCT06215716 RECRUITING
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc n=1,650
NCT06318169 RECRUITING
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
89bio, Inc. n=1,350
NCT07221188 RECRUITING
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
GlaxoSmithKline n=1,250
NCT07219602 NOT YET RECRUITING
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NewAmsterdam Pharma n=300
NCT07221227 RECRUITING
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
GlaxoSmithKline n=1,200
NCT06161571 ACTIVE NOT RECRUITING
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Akero Therapeutics, Inc n=700
NCT05935826 RECRUITING
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
University of Colorado, Denver n=55
NCT07065357 ENROLLING BY INVITATION
Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor
The University of Hong Kong n=160
NCT04951219 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals, Inc. n=1,000
NCT04833140 RECRUITING
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Massachusetts General Hospital n=60
NCT06908473 ENROLLING BY INVITATION
Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients
Guangdong Provincial Hospital of Traditional Chinese Medicine n=530
NCT05500222 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Madrigal Pharmaceuticals, Inc. n=700
NCT06884293 RECRUITING
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Innovent Biologics (Suzhou) Co. Ltd. n=470
NCT05073835 ACTIVE NOT RECRUITING
Semaglutide 2.4 mg in Patients With Poor Weight-loss
University College, London n=70
NCT05905965 RECRUITING
Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment
Collegium Medicum w Bydgoszczy n=200
NCT03900429 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals, Inc. n=1,759
NCT04849728 RECRUITING
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Inventiva Pharma n=1,000
NCT06152991 ENROLLING BY INVITATION
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
Yoon Jun Kim n=196
NCT04365868 TERMINATED
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Galectin Therapeutics Inc. n=357
NCT06309992 COMPLETED
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight
Boehringer Ingelheim n=218
NCT04104321 SUSPENDED
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
Galmed Research and Development, Ltd. n=157
NCT03919929 COMPLETED
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
University of Colorado, Denver n=60
NCT03355469 COMPLETED
Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome
Rutgers University n=91
NCT06692283 WITHDRAWN
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
Sagimet Biosciences Inc.
NCT06594523 WITHDRAWN
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Sagimet Biosciences Inc.
NCT03031821 TERMINATED
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Canadian Urologic Oncology Group n=168
NCT02548351 TERMINATED
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Intercept Pharmaceuticals n=2,477
NCT05284448 COMPLETED
Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis
Al-Azhar University n=50
NCT06348706 COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
Ain Shams University n=60
NCT03723252 COMPLETED
Dapagliflozin Efficacy and Action in NASH
Nanfang Hospital, Southern Medical University n=154
NCT02541045 WITHDRAWN
Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
Hospital General de Mexico
NCT04237116 TERMINATED
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
Novartis Pharmaceuticals n=10
NCT05768334 COMPLETED
Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
Helwan University n=116
NCT03439254 COMPLETED
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Intercept Pharmaceuticals n=919
NCT04197479 COMPLETED
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Madrigal Pharmaceuticals, Inc. n=1,343
NCT05457530 WITHDRAWN
Doravirine and Weight Gain in Antiretroviral Naive
Prism Health North Texas
NCT03633630 COMPLETED
Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
University of Guadalajara n=28
NCT04142749 COMPLETED
Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis
PharmaKing n=146
NCT05521633 COMPLETED
Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver
King Edward Medical University n=96
NCT02704403 TERMINATED
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Genfit n=2,157
NCT03028740 TERMINATED
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
Tobira Therapeutics, Inc. n=1,778
NCT02983188 COMPLETED
Berberine as Adjuvant Treatment for Schizophrenia Patients
The University of Hong Kong n=113
NCT03585413 COMPLETED
Impact of a Specific Micronutrient-probiotic-supplement on Fatty Liver of Patients After Mini-Gastric Bypass Surgery
Bonn Education Association for Dietetics r.A., Cologne, Germany n=60
NCT03053050 TERMINATED
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Gilead Sciences n=808
NCT04411862 COMPLETED
Efficacy of Phosphatidylcholine in NAFLD
Nehal Abou Seada n=100
NCT03053063 TERMINATED
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences n=883
NCT02991209 COMPLETED
Study of Testosterone vs Placebo in Testicular Cancer Survivors
Mikkel Bandak n=69
NCT03490097 COMPLETED
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
Ain Shams University n=100
NCT02842567 COMPLETED
Hydroxytyrosol and Vitamin E in Pediatric NASH
Bambino Gesù Hospital and Research Institute n=80
NCT02764957 COMPLETED
Green Coffee Extract and Metabolic Syndrome
National Nutrition and Food Technology Institute n=43
NCT02672592 COMPLETED
Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome
University Hospital, Basel, Switzerland n=70
NCT02216552 COMPLETED
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
University of Manitoba n=10

Data: ClinicalTrials.gov